BIOR: Biora Therapeutics Inc. Company Value to Net Income

Symbol and logo of brand Biora Therapeutics Inc. (BIOR)

The market value dynamics of Biora Therapeutics (BIOR), which has a multiplier of -0.10, are based on the creation of electronic pills for targeted gastrointestinal impact, protected by patents and massive research investments. The business relies on the development of smart capsules, overcoming certification complexities and the capital intensity of trials. Stringent FDA technological filters and microelectronic developments reliably insulate the niche from new entrants.

BIOR Biora Therapeutics, Inc. P/E Multiple (04/28/2023 - 12/14/2024)

Comprehensive metric breakdowns and analytics for Biora Therapeutics (BIOR)

- price and consensus price forecast:
Stock Price Progenity|BIOR - Consensus Target
- market capitalization information:
Market Value Biora Therapeutics Inc.|BIOR - Enterprise Value
- balance sheet net asset value indicators:
Book Value of One Share Biora Therapeutics|BIOR - Book Capitalization|Market Capitalization to Book Value bioratherapeutics.com|BIOR - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Biora Therapeutics|BIOR - Long-Term Debt to Capital|Short-Term Debt to Equity Biora Therapeutics|BIOR - Company Aggregate Debts|Debts to Net Assets Progenity|BIOR - Company Long-Term Debt|Short-Term Debt Biora Therapeutics|Intermediate Coverage Ratio bioratherapeutics.com
- earnings and multiples data:
BIOR - Net Profit|Projected Future Earnings Biora Therapeutics|BIOR - Price to Earnings Ratio|Future Price to Earnings Multiple Biora Therapeutics|BIOR - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Biora Therapeutics Inc.|BIOR - Operating profit EBITDA|Earnings per share for the trailing year Biora Therapeutics|BIOR - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months bioratherapeutics.com|BIOR - Earnings per share growth in current year|Expected earnings per share trend next year Biora Therapeutics
- company sales and revenue statistics:
BIOR - Revenue and Sales Volume|Projected Sales Volume Biora Therapeutics Inc.|BIOR - Price-to-Revenue Ratio|Future Price to Revenue Biora Therapeutics Inc.|BIOR - Sales Growth YoY (TTM)
Summary company analysis:Biora Therapeutics
Finished products of Biora Therapeutics, Inc

A defensive portfolio is constructed through rigorous screening of value multiples. This indicator compares a business's market value to its annual net income to determine the investment payback period. For Biora Therapeutics (BIOR), which is currently in a capital-burning phase and developing NaviCap, this metric reflects the speculative nature of its valuation. It is critical for investors to monitor the current P/E ratio of Biora Therapeutics (BIOR) to identify whether the asset is overbought.

Analysis of competing companies

P/E Multiple Phathom Corp|Price to Earnings Ratio TERN (Terns Pharmaceuticals Inc)|IRWD (Ironwood Pharmaceuticals, Inc.) - Company Value to Net Income|P/E Multiple CURX (Curanex)|Market Cap to Net Income Ratio Immuron Inc|Evoke Pharma Inc. - P/E Multiple|Business Payback Period Entero Therapeutics Inc. ENTO|RDHL (redhillbio.com) - Price to Earnings Ratio|PALI: Market Price to Net Income Ratio|Price to Earnings Ratio Jaguar Animal Health|Price to Earnings Ratio morphictx.com (MORF)